Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gardasil 9 in HIV-infected and solid organ transplant adults
2017-004322-15Phase 3Completed
- Sponsor
- UZ Leuven
- Start
- Dec 2017
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of recombinant human papillomavirus 9-valent vaccine in human papillomavirus infection (2 arms), sponsored by UZ Leuven. Primary endpoint: Immunogenicity against HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58. Started Dec 2017; status: completed.
02
Drugs
recombinant human papillomavirus 9-valent vaccine
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on 2017-004322-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004322-15.